The therapeutic effect of chemotherapy on central neuroblastoma

Central neuroblastoma (CN) is a rare central nervous system tumor that is a WHO II grade and generally has a good prognosisThe tumor is well-developed in the lateral ventricle and the triencephaliary ventricle, often accompanied by obstructive hydrocephalusThe main treatment methods are surgical excision and radiation therapyIt is generally believed that the Ki67 proliferation index is higher than 2% or 3% of central neuroblastoma has atypical characteristicsMany doctors try chemotherapy to treat difficult surgically resectiond and highly invasive central neuroblastoma, but there are many options and no guidelines or consensus guidance on medicationMargaret O Johnson of Neurosurgery at Duke University Hospital in the United States conducted retrospective studies that targeted the value of chemotherapy in the treatment of central neuroblastoma, and the results were published in the November 2019 issue of CNS Oncologyresearch methodology
the clinical data of the study consists of two parts, one for the researchers to consult patients with central neuroblastoma at Duke University Hospital from 2004 to 2016, and the other is a paper on the treatment of central neuroblastoma in the PubMed databaseIt should be noted that the cases in this study did not include central neuroblastoma sedatomas of the non-ventricle systembetween 2004 and 2016, only one of the nine patients diagnosed with central neuroblastoma at Duke University Hospital received chemotherapyThe Ki-67 of the patient's tumor cells is up to 20%The tumor recurs 6 years and 10 months after surgery and radiotherapyAfter the complete removal of the tumor again, a 5.5-week combination of simultaneous chemotherapy was performed, with daily TMZ doses of 75 mg/m2 and 1.8Gy radiation, totalling 50.4GyAt present, patients have been able to work and live normally for 14 years since the onset of the diseasethe results wereretrieved through the PubMed database, and the researchers found that 36 patients in 18 literatures were diagnosed with central neuroblastoma for chemotherapySince 1991, chemotherapy drugs have been used, including nemostin, lomustine, carmostine, cyclophosphamide, isocyclophosphamide, cisplatin, caplatinum, etoposide, changchunneoline, amycin, renimastin, immatainib, Ilitocon and tamoxifen Since the introduction of TMZ in 2005, almost all in-the-system surgeons have used TMZ as the preferred drug for central neuroblastoma, and also for recurrent central neuroblastomas at doses of 75-200 mg/m2/day and cycles of 5-42 days, accompanied or not accompanied by simultaneous radiation therapy In patients with tumor recurrence with tamoxamine, the survival of disease without progression ranged from 9 to 6 years and 9 months conclusions
the study is the first to review the treatment of central neuroblastoma with chemical drugs for reference when clinicians treat central neuroblastoma with a high proliferation index The author points out that temolymine is the main drug in chemotherapy for central neuroblastoma, but its efficacy is worthy of further study and verification.